Heron Therapeutics (HRTX) Q2 2025: Acute Care Franchise Grows 55%, Restructuring Targets Second-Half Acceleration
Acute care product demand surged double digits, but inventory normalization and salesforce restructuring masked underlying momentum. Heron’s refinancing and cost discipline reset the balance sheet, while the permanent J code for Zynrelef and new commercial focus set up a potential inflection for the second half. Investors should watch for translation of unit growth into reported revenue as channel headwinds abate and commercial payers align with new reimbursement trends.
Summary
- Acute Franchise Unit Growth: Zynrelef and Oponv demand outpaced net revenue, reflecting real-world adoption strength.
- Commercial Realignment: Dedicated sales teams and targeted incentives aim to unlock hospital conversion and accelerate pull-through.
- Second-Half Setup: Inventory normalization and J code adoption position Heron for a sharper revenue inflection ahead.
Performance Analysis
Heron’s acute care franchise delivered 55.5% year-over-year net revenue growth in Q2, with Zynrelef and Oponv reaching $10.7 million for the quarter. Oncology supportive care products, Symbonti and Sustol, provided stability with $26.5 million in quarterly revenue, maintaining share despite a competitive environment. While reported total net revenue of $37.2 million was relatively flat sequentially, this masks double-digit unit growth and expanding account penetration, particularly for Zynrelef, which saw 6.3% sequential unit growth and surpassed 700 ordering accounts.
Gross margin improved to 73.5%, driven by higher sales volumes and product mix, while SG&A and R&D expenses declined year-over-year due to workforce reductions and lower write-offs. Adjusted EBITDA swung positive to $1.8 million for the quarter, up from a loss last year, and net loss narrowed sharply. The refinancing closed in August, extinguishing near-term debt and adding $11–12 million in net cash, further stabilizing the capital base.
- Inventory Headwinds: Acute care revenue was dampened by a $400,000 wholesaler inventory drawdown tied to the 400mg Zynrelef transition, with normalization expected in Q3.
- Salesforce Reorganization: Dedicated teams for Zynrelef and Oponv, with targeted Crosslink incentives, aim to convert formulary access into utilization.
- Oncology Stability: Symbonti and Sustol continue to anchor cash flow, offsetting acute care volatility.
Management maintained full-year revenue guidance and raised EBITDA expectations, signaling confidence in operational leverage and cost controls as channel dynamics stabilize.
Executive Commentary
"One of the most significant milestones this quarter was the successful completion of our new financing. This was a complex and critical undertaking, and I'm proud to say our team executed it with precision and focus as usual. The financing strengthens our balance sheet, enhances our financial flexibility, and positions us to accelerate our strategic initiatives with confidence."
Craig Collard, Chief Executive Officer
"Our product gross profit for the three months ended June 30th, 2025 was $27.3 million or 73.5%, which increased from 70.8% for the same period in 2024... For the three months ended June 30th, 2025, we incurred a net loss of $2.4 million compared to a net loss of $9.2 million for the same period in 2024."
Ira Duarte, Chief Financial Officer
Strategic Positioning
1. Acute Care Franchise Realignment
Heron’s acute care business, led by Zynrelef and Oponv, is at the center of the company’s growth thesis. The transition to a permanent J code for Zynrelef, effective October, is a pivotal reimbursement milestone, expected to lower administrative barriers and improve access, especially as commercial payers increasingly mirror Medicare’s No Pain Act mandates. The organization is leveraging targeted pull-through in accounts with formulary access and deploying a new clinical educator team to boost onboarding efficiency in high-volume centers.
2. Commercial Execution Reset
The salesforce restructuring split Zynrelef and Oponv into dedicated teams, recognizing the distinct selling environments—operating room versus traditional hospital. The Crosslink partnership, now focused on high-potential accounts with enhanced per-unit incentives, is designed to convert formulary wins into real utilization. This approach, paired with territory consolidation, was executed without incremental headcount, signaling a focus on efficiency and ROI.
3. Oncology Franchise as Cash Flow Anchor
Symbonti and Sustol continue to deliver consistent revenue and market share, providing a stable base as Heron invests in acute care expansion. Management is exploring additional strategies to drive growth in oncology supportive care, but the primary narrative is one of stability and predictability in a competitive landscape.
4. Financial Discipline and Balance Sheet Reset
The August refinancing package retires near-term debt and injects fresh capital, with a new $150 million credit facility, convertible notes, and equity raise. This strengthens Heron’s ability to invest in growth initiatives and weather potential reimbursement or channel shocks, while maintaining a disciplined approach to cost structure and expansion pacing.
Key Considerations
Heron’s Q2 was defined by operational groundwork rather than headline revenue growth, with acute care demand and commercial alignment setting up a second-half acceleration. The interplay between reimbursement, channel inventory, and salesforce focus is central to the investment case.
Key Considerations:
- Reimbursement Tailwinds: The J code for Zynrelef and No Pain Act momentum could drive a step-change in adoption as payer acceptance broadens.
- Salesforce Leverage: Dedicated and incentivized teams are expected to improve pull-through, but execution risk remains as new structures are tested.
- Inventory Normalization: Acute care revenue should better reflect underlying demand in the second half as wholesaler inventories rebalance.
- Cost and Cash Discipline: SG&A and R&D reductions, paired with refinancing, provide a stable runway for measured investment in growth.
Risks
Heron faces several execution and market risks, including the pace of commercial payer adoption of new reimbursement codes, potential delays in inventory normalization, and the ability of the restructured salesforce to deliver on pull-through targets. Competitive intensity in both acute care and oncology supportive care could pressure pricing or share, while macro reimbursement shifts remain a wildcard.
Forward Outlook
For Q3 and the remainder of 2025, Heron guided to:
- Full-year net revenue of $153 million to $163 million (unchanged)
- Adjusted EBITDA revised upward to $9 million to $13 million (from $4 million to $12 million)
Management cited several drivers for the outlook:
- Normalization of acute care channel inventory and continued unit growth
- Permanent J code and evolving payer landscape to support adoption
Takeaways
Heron’s Q2 was a foundational quarter, with operational and financial moves positioning the business for a potential second-half acceleration as reimbursement and commercial execution converge.
- Acute Care Inflection Point: Underlying demand and adoption are robust, but reported results will lag until inventory and payer dynamics fully align.
- Commercial Execution is Central: The effectiveness of dedicated teams and incentive structures will determine whether demand translates into sustainable revenue growth.
- Balance Sheet Strength Provides Flexibility: Recent refinancing and cost controls give Heron room to invest and adapt as the reimbursement landscape evolves.
Conclusion
Heron enters the second half of 2025 with acute care momentum, streamlined operations, and a strengthened balance sheet. The next two quarters will be critical in validating the commercial and reimbursement strategies now in place.
Industry Read-Through
Heron’s experience this quarter offers a lens into the broader specialty pharma landscape, where reimbursement clarity and commercial execution increasingly dictate success. The transition from C codes to permanent J codes, and the operationalization of the No Pain Act, will be key themes for peers in acute care and hospital-administered therapeutics. Inventory normalization and salesforce specialization are likely to become best practices as companies seek to bridge the gap between formulary access and real-world utilization. Investors should monitor how quickly payers and hospital systems adapt to new reimbursement structures, as this will shape adoption curves across the sector.